GROUP – A (LAQ-15 MARKS) 1. Define screening. List and briefly describe the criteria for a good screening test. List and briefly describe the features of a disease which makes it suitable for screening. (3+6+6 = 15) [JNM] GROUP – B (SAQ-10 MARKS) 1. A screening test for diabetes mellitus has a sensitivity of 95% and specificity of 80%. • Define sensitivity and specificity. (2 Marks) • Why is high sensitivity preferred in a screening test? (1 Mark) • Mention one screening test recommended under NP-NCD for diabetes mellitus. (1 Mark) [DHGMCH] 2. Define screening. What is the difference between screening and case finding? For screening of a fatal disease, will you consider false positive or false negative and why?( 2 + 4 + 4 = 10) [BSMCH] 3. What is opportunistic screening? Mention name of two diseases of public health importance where opportunistic screening can be applied. What are the criteria of a screening test? Write down difference between screening and diagnostic test. (2+2+3+3) [MCK] GROUP – C (S/N-5 MARKS) 1. Validity of screening test [MJNMCH] 2. Lead Time Screening. [SMCH] GROUP – D (E/W-4 MARKS) 1. Sensitivity and specificity of a diagnostic test are inversely related. [MMC] [CNMCH] 2. An ideal screening test needs some criteria to be fulfilled. [KPC] [JMNMCH] 3. Sensitivity and Specificity of a screening test are inversely related. [SRIMS] 4. A highly sensitive test is generally preferred for screening, whereas a highly specific test is preferred for definitive diagnosis.[NRS] 5. A highly sensitive test is preferred when screening for serious but treatable diseases. [NBMCH] 6. Sensitivity & specificity are reciprocally related. [JIMSH] 7. Positive Predictive Value of a screening test is related to the prevalence of the disease. [JHARGRAM] 8. Lead time in a screening test gives false statement about survival period of patients. Justify. [DMGMCH] [ESIC JOKA] 9. Positive predictive value will increase when the test is applied in a high-risk population with sensitivity and specificity remaining constant – comment. [CMSDH] 10. Premarital screening for thalassemia is essential. [BSMCH]

Reading File

Finding Sources

Reading File

I now have sufficient content from Park's Textbook of Preventive and Social Medicine to write comprehensive answers to all the questions. Let me compile the full answer set.

COMPREHENSIVE ANSWERS: SCREENING

Source: Park's Textbook of Preventive and Social Medicine (Park); Textbook of Family Medicine 9e (TFM)

GROUP A - LAQ (15 Marks)

Q1. Define Screening. Criteria for a good screening test. Features of a disease suitable for screening. (3+6+6 = 15)

DEFINITION OF SCREENING (3 Marks)

Screening is the presumptive identification of unrecognized disease or defect by the application of tests, examinations, or other procedures which can be applied rapidly to sort out apparently well persons who probably have a disease from those who probably do not.

It is a presumptive (not definitive) identification - a positive screen is not a diagnosis.
Screening tests sort out apparently healthy people.
They must be followed by confirmatory diagnostic tests.

(Wilson & Jungner, 1968 - WHO criteria; Park's PSM)

CRITERIA FOR A GOOD SCREENING TEST (6 Marks)

A screening test must satisfy the following criteria:

1. Acceptability The test must be acceptable to the population it targets. Painful, embarrassing, or invasive procedures (e.g., rectal or vaginal examinations) are poorly accepted in mass campaigns and reduce participation rates.

2. Repeatability (Reliability / Precision) The test must give consistent results when repeated on the same individual under the same conditions. Repeatability depends on:

Observer variation - intra-observer (same observer, different readings on same subject) and inter-observer (different observers on the same subject)
Biological variation - natural fluctuation of physiological variables (e.g., blood pressure, blood glucose)
Technical errors - faulty instruments, reagents, calibration

3. Validity (Accuracy) Validity is the ability of a test to correctly distinguish those who have the disease from those who do not. It has two components:

Component	Definition	Formula
Sensitivity	Proportion of true disease cases correctly identified as positive	TP / (TP + FN) × 100
Specificity	Proportion of truly non-diseased persons correctly identified as negative	TN / (TN + FP) × 100

Sensitivity and specificity are inversely related - raising the cut-off increases specificity but lowers sensitivity and vice versa.
An ideal test should be 100% sensitive and 100% specific, but this is rarely achievable in practice.

4. Yield Yield is the amount of previously unrecognized disease diagnosed as a result of screening. It depends on sensitivity/specificity of the test, prevalence of the disease in the screened population, and proportion of the population actually screened.

5. Simplicity, Safety, and Rapidity The test should be simple enough for paramedical staff to perform, safe (no/minimal risk to the patient), and rapid (to process large numbers in short time).

6. Cost The cost of the test should be reasonable and acceptable in relation to benefits gained. The benefit-cost ratio should favor screening.

FEATURES OF A DISEASE SUITABLE FOR SCREENING (6 Marks)

Based on the WHO criteria (Wilson & Jungner), a disease is suitable for screening if:

1. Important health problem The disease should be of significant public health importance with high prevalence or severe consequences (e.g., cervical cancer, diabetes, hypertension).

2. Recognizable latent or early asymptomatic stage There must be a detectable preclinical or presymptomatic phase during which the disease is identifiable but has not yet caused irreversible damage (e.g., CIN for cervical cancer, impaired fasting glucose for diabetes).

3. Understood natural history The natural history of the disease - from latent to declared - must be adequately understood, so we know at what stage the process becomes irreversible. Without this knowledge, early detection may not be meaningful.

4. A suitable detection test exists There must be a test that can detect the disease prior to the onset of signs and symptoms, and that test must meet the criteria of validity, repeatability, and acceptability.

5. Facilities available for confirmatory diagnosis After a positive screen, diagnostic confirmation must be feasible. Screening without follow-up diagnostic infrastructure is unethical and futile.

6. Effective treatment available Treatment that can alter the course of the disease must exist. Screening for a disease with no effective treatment gives no benefit and may cause harm through anxiety.

7. Agreed policy on management There should be an agreed-upon policy about what constitutes a "positive" case and how borderline results are managed (e.g., borderline blood glucose, borderline blood pressure ranges).

8. Early detection reduces morbidity and mortality There must be good evidence that detecting the disease earlier (before it becomes symptomatic) significantly reduces morbidity and mortality compared to treatment at symptomatic stage.

9. Benefits outweigh risks and costs The expected benefits (lives saved, morbidity prevented) must exceed the risks (false positives, anxiety, unnecessary investigations, treatment side effects) and financial costs.

GROUP B - SAQ (10 Marks)

Q1. Screening test for DM: sensitivity 95%, specificity 80% (DHGMCH)

a) Define Sensitivity and Specificity (2 Marks)

Sensitivity: The proportion of truly diseased persons in the screened population who are identified as diseased by the screening test.
- Formula: Sensitivity = True Positives / (True Positives + False Negatives) × 100
- A highly sensitive test rarely misses disease ("SNOUT" - Sensitive test, Negative result rules OUT disease)
Specificity: The proportion of truly non-diseased persons who are so identified by the screening test.
- Formula: Specificity = True Negatives / (True Negatives + False Positives) × 100
- A highly specific test rarely labels healthy people as diseased ("SPIN" - Specific test, Positive result rules IN disease)

In this scenario: the test correctly identifies 95% of diabetics (high sensitivity, few false negatives) but only 80% of non-diabetics (moderate specificity, 20% false positive rate).

b) Why is high sensitivity preferred in a screening test? (1 Mark)

High sensitivity is preferred in screening because the primary goal of screening is to not miss cases - false negatives (missed disease cases) are more dangerous than false positives (unnecessary referral). For serious diseases like DM, missing a case means the person goes untreated and suffers preventable complications. False positives only require further confirmatory testing. Additionally, the motto of screening is: "cast a wide net" - confirmed later by specific diagnostic tests.

c) Screening test recommended under NP-NCD for Diabetes Mellitus (1 Mark)

Under the National Programme for Non-Communicable Diseases (NP-NCD), the recommended screening test for diabetes mellitus is:

Fasting Blood Glucose (FBG) or Random Blood Glucose (RBG)
- RBG ≥ 140 mg/dL or FBG ≥ 100 mg/dL considered screen-positive; confirmed by repeat FBG or OGTT.
Also: HbA1c is increasingly used as a screening/diagnosis tool.

Q2. Define Screening. Screening vs Case Finding. Fatal disease: FP or FN? (2+4+4 = 10) (BSMCH)

Definition of Screening (2 Marks) (As above - presumptive identification of unrecognized disease in apparently healthy individuals.)

Difference between Screening and Case Finding (4 Marks)

Feature	Screening	Case Finding
Population	Mass, apparently healthy	Individual presenting to physician for another reason
Initiative	Initiated by health authority	Initiated by physician (opportunistic)
Also called	Mass screening, community screening	Opportunistic screening
Example	Door-to-door survey for TB	Testing blood pressure in a patient attending OPD for a headache
Coverage	Large population	Smaller, selected individuals
Cost	High	Relatively low
Ethics	Must consider risk-benefit to whole population	Primarily for benefit of the individual

False Positive vs False Negative for a Fatal Disease (4 Marks)

For screening a fatal but treatable disease:

False Negative (FN) is more dangerous and should be avoided.
A false negative means a diseased person is labeled as healthy - they go undetected, receive no treatment, and may die from the disease. This defeats the entire purpose of screening.
A false positive means a healthy person is labeled as "probably diseased" - they undergo further confirmatory testing, experience anxiety, but are subsequently cleared. This is less harmful.
Therefore, for a fatal disease, we prefer a highly sensitive test (which minimizes false negatives), even at the cost of accepting more false positives.
The false positives are then filtered out by subsequent confirmatory (highly specific) diagnostic tests.

Q3. Opportunistic Screening - Criteria - Screening vs Diagnostic Test (2+2+3+3) (MCK)

Opportunistic Screening (2 Marks)

Opportunistic screening (= case finding) is the screening of individuals who are attending a health facility for some other purpose. The health worker uses the opportunity of contact to screen for another condition. It is not pre-planned for a population but occurs opportunistically.

Examples of diseases for opportunistic screening (2 Marks):

Hypertension - Blood pressure measured in any patient attending OPD
Cervical Cancer - Pap smear offered to women attending family planning clinic
Diabetes Mellitus - Blood glucose checked in patients admitted for surgery
HIV - Offered at antenatal care visits

Criteria of a Screening Test (3 Marks) (Summarized from above: Acceptability, Repeatability, Validity [sensitivity/specificity], Yield, Simplicity, Safety, Cost)

Difference between Screening and Diagnostic Test (3 Marks)

Feature	Screening Test	Diagnostic Test
Purpose	Presumptive identification of disease	Definitive confirmation of disease
Population	Large, apparently healthy	Individuals with symptoms or positive screen
Sensitivity/Specificity	High sensitivity prioritized	High specificity prioritized
Cost	Inexpensive	May be expensive
Invasiveness	Non-invasive/minimally invasive	May be invasive
Result	"Probably has/does not have disease"	"Definitely has/does not have disease"
Follow-up	Always requires diagnostic confirmation	Final decision made here
Example	Pap smear, FBG for DM	Colposcopy + biopsy, OGTT

GROUP C - Short Notes (5 Marks)

C1. Validity of a Screening Test

Validity refers to the ability of a screening test to accurately separate those who have the disease from those who do not. It is also called accuracy.

Validity has two components:

1. Sensitivity

The ability of the test to identify correctly all those who have the disease (true positive rate)
Sensitivity = TP / (TP + FN) × 100
A sensitive test has few false negatives
High sensitivity = "SNOUT" (rules OUT disease when negative)

2. Specificity

The ability of the test to identify correctly all those who do not have the disease (true negative rate)
Specificity = TN / (TN + FP) × 100
A specific test has few false positives
High specificity = "SPIN" (rules IN disease when positive)

Predictive Values (also part of validity assessment):

PPV (Positive Predictive Value) = TP / (TP + FP) × 100 = probability that a person with a positive test truly has the disease
NPV (Negative Predictive Value) = TN / (TN + FN) × 100 = probability that a person with a negative test truly does not have the disease
Unlike sensitivity/specificity, predictive values depend on disease prevalence - PPV rises with higher prevalence; NPV falls with higher prevalence

Sensitivity-Specificity Trade-off:

They are inversely related. Moving the cut-off point one way increases one at the expense of the other.
An ideal test has both at 100% - this is practically unachievable.

C2. Lead Time in Screening

Definition: Lead time is the period between the detection of disease by screening and the time it would have been detected based on the appearance of clinical symptoms (i.e., the time by which diagnosis is advanced due to screening).

Diagram concept:

Biological onset → [PRECLINICAL DETECTABLE PHASE] → Symptoms → Death
                   ↑ Screen detects here           ↑ Clinical detection
                   |←------- LEAD TIME ----------->|

Importance:

Lead time is the "head start" given by screening - the window during which early treatment may alter the disease course.
The longer the lead time, the wider the detectable preclinical phase, and the greater the potential benefit of screening.

Lead Time Bias: This is a critical concept. If a disease is detected earlier by screening but the ultimate date of death is unchanged, the patient appears to "survive longer after diagnosis" - but this is only because diagnosis was made earlier, not because prognosis improved. This is lead time bias - it gives a false impression of improved survival (addressed in GROUP D, Q8).

GROUP D - Essay/Write (4 Marks)

D1/D3/D6. Sensitivity and Specificity are Inversely Related

This is a fundamental property of any screening test with a continuous measurement variable:

As the cut-off point is lowered (e.g., lowering blood glucose threshold from 180 to 140 mg/dL for DM screening):
- More diseased persons are captured → Sensitivity increases
- More non-diseased persons are also labeled positive → Specificity decreases
As the cut-off point is raised:
- Fewer false positives → Specificity increases
- More diseased persons are missed → Sensitivity decreases

This is illustrated by Park's Table 6 (2-hour post-prandial glucose for DM):

Blood glucose cut-off	Sensitivity	Specificity
80 mg/dL	100%	1.2%
130 mg/dL	81.4%	82.4%
200 mg/dL	37.1%	100%

As sensitivity approaches 100%, specificity approaches 0%, and vice versa. The optimal cut-off (often chosen by ROC curve) balances both. An ideal screening test with 100% sensitivity AND 100% specificity does not exist in practice.

D2 / D1 (KPC/JMNMCH). An ideal screening test needs some criteria to be fulfilled

An ideal screening test must satisfy criteria related to:

Acceptability - acceptable to the screened population (non-invasive, non-embarrassing)
Repeatability - consistent results on repeat testing (minimal observer/biological/technical variation)
Validity - high sensitivity (few missed cases) and high specificity (few false alarms)
Yield - detects sufficient previously unrecognized disease to justify cost
Simplicity - can be performed by paramedical staff in field conditions
Safety - no or minimal risk to the screened person
Rapidity - can process large numbers quickly
Low cost - affordable for mass application; cost-benefit ratio must be favorable

(Park's PSM - Criteria for Screening Test)

D4 / D5. High Sensitivity Preferred for Screening; High Specificity for Definitive Diagnosis

For Screening - High Sensitivity:

The primary goal is to not miss any case of disease.
False negatives (missed cases) are far more harmful than false positives (unnecessary referrals).
A missed case of a serious disease (cancer, TB) means delayed/absent treatment, progressive disease, and avoidable death.
False positives only result in further testing (confirmatory diagnosis) and temporary anxiety.
Example: Mantoux test for TB has high sensitivity.

For Definitive Diagnosis - High Specificity:

The goal here is to definitively confirm disease; we must not label a healthy person as diseased.
A false positive at this stage leads to inappropriate, potentially harmful treatment.
Example: Sputum AFB smear/culture for TB; biopsy for cancer.

The Two-Step Approach in Practice:

Screen with a sensitive test (wide net, catches all possible cases)
Confirm positives with a specific test (confirms true disease, rules out false positives)

Example: RPR (sensitive) for syphilis screening → TPHA/FTA-ABS (specific) for confirmation.

D7 / D9. Positive Predictive Value (PPV) is Related to Prevalence

PPV = TP / (TP + FP) × 100

PPV indicates the probability that a person with a positive test result actually has the disease.

Relationship to Prevalence:

PPV is NOT an inherent property of the test alone - it varies with disease prevalence in the tested population.
When prevalence is high (high-risk population): more true positives, fewer false positives → PPV rises
When prevalence is low (general population): more false positives relative to true positives → PPV falls

Numerical example: Assume Sensitivity = 95%, Specificity = 80%, in two populations:

Population	Prevalence	True +ve	False +ve	PPV
Low-risk	1% (10/1000)	9.5 (~10)	198	10/(10+198) = ~5%
High-risk	20% (200/1000)	190	160	190/(190+160) = ~54%

This confirms: In a high-risk population, PPV will increase even with the same sensitivity and specificity - because the pre-test probability (prevalence) is higher.

Practical implication: Selective screening of high-risk groups (targeted screening) is more efficient than mass screening for low-prevalence diseases, as it maximizes PPV and reduces unnecessary follow-up investigations.

(Park's PSM - Predictive Accuracy)

D8. Lead Time Gives False Statement About Survival Period - Justify

Lead Time Bias refers to the apparent lengthening of survival time after diagnosis that results purely from earlier diagnosis by screening, without any actual prolongation of life.

Explanation:

Suppose a patient's disease begins biologically at time 0, would be diagnosed symptomatically at year 5, and the patient would die at year 8.
Without screening: diagnosed year 5, lived 3 years after diagnosis (survival = 3 years)
With screening: diagnosed year 2, still dies at year 8 (survival = 6 years)

The patient died at the same time, but appears to have survived 6 years instead of 3 years - purely because of earlier diagnosis.

Why this is a false statement about survival:

Screening did NOT change the biological course or date of death.
It only moved the time of diagnosis earlier.
Therefore, survival statistics from screened populations overestimate the benefit of screening unless corrected for lead time.

How to correct for it:

Compare age-adjusted cause-specific death rates between screened and unscreened populations (not survival time after diagnosis).
The gold standard is a Randomized Controlled Trial comparing screened vs. unscreened groups on mortality endpoints.

D10. Premarital Screening for Thalassemia is Essential

Why it is essential:

1. Epidemiological burden:

Thalassemia is the most common hereditary haemolytic anaemia in India.
Beta-thalassemia major is a fatal disease requiring lifelong blood transfusions.
Carrier frequency in India is ~3-4%; higher in certain communities (Sindhis, Punjabis, Gujaratis, Bengalis).

2. Disease criteria met:

Important health problem (high prevalence of carriers)
Recognizable preclinical (carrier) stage
Understood Mendelian inheritance: two carriers have 25% chance of an affected child
Effective test available: CBC + HbA2 estimation (HbA2 > 3.5% identifies beta-thalassemia trait)
No curative treatment except bone marrow transplantation (costly, limited)
Prevention is more effective than cure

3. Prevention logic:

Identifying two carrier partners before marriage allows:
- Informed reproductive decision-making
- Prenatal diagnosis if both partners are carriers (chorionic villus sampling at 10-12 weeks)
- Option of not marrying / not having children / using donor gametes
Cost of prevention << cost of treating a thalassemia major child lifelong

4. Ethical basis:

Voluntary, with genetic counseling
Supported by government programs (National Health Mission)

Screening test: Hemoglobin electrophoresis / HPLC to detect HbA2 elevation (> 3.5%) identifying beta-thalassemia trait.

Sources: Park's Textbook of Preventive and Social Medicine, 26th Edition; Textbook of Family Medicine 9e (Rakel)

This is a shared conversation. Sign in to Orris to start your own chat.